Skip to main content

Table 1 Data from the study population

From: Evaluation of retinal microvascular perfusion in hereditary angioedema: a case-control study

 HAE (n = 20)HC (n = 20)
Age (years)41.3 ± 13.545 ± 13
Female sex (N/%)10/5011/55
HAE disease duration (years)27.4 ± 14N.A.
Number of attacksa8 ± 7.6N.A.
Attack-free period (days)b59 ± 71N.A.
Danazol prohylaxis (N/%)4/20N.A.
C4 (mg/dl)9.5 ± 4.5N.A.
C1q (mg/l)146 ± 20.3N.A.
C1INH (mg/dl)7 ± 3.4N.A.
C1INH (%)27.6 ± 12.2N.A.
MABP (mmHg)89 ± 10.488 ± 8
BCVA (LogMAR)0.01 ± 0.1 (R); 0.01 ± 0.1 (L)0.013 ± 0.03
IOP (mmHg)16.5 ± 3 (R); 16.7 ± 2.9 (L)16 ± 3
MD (median, dB)−1.9 ***(R); − 2 ***(L)0.3
PSD (median, dB)2.16 **(R); 1.9 *(L)1.6
VFI (range %)92–9898–100
  1. HAE hereditary angioedema, HC healthy controls, C1INH C1 inhibitor, MABP mean arterial blood pressure, BCVA best corrected visual acuity, IOP intraocular pressure, MD mean deviation, PSD Pattern Standard Deviation, VFI visual field index, R right eyes, L left eyes. Continuous variables were shown using mean and standard deviation (SD) while categorical variables with absolute frequencies and percentages. Values from patients were compared with controls using the parametric unpaired T test or the nonparametric Mann–Whitney U test when appropriate and P values < 0.05 were considered significant (*p < 0.05, **p < 0.01, ***p < 0.001, with the respect to control eyes). anumber of HAE attacks in the last 12 months; bnumber of days from the last acute attack to the time of the visit